Treatment | UFAsi | UFAsii (ng·mg−1 FW) | SFAsii (ng·mg−1 FW) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
(ng·mg−1 FW) | (%, in the total FAs) | C16.1 | C18.1N9 | C18.2N6 | C18.3N6 | C16.0 | C18.0 | C20.0 | C22.0 | C24.0 | |
W | |||||||||||
NM | 193.66 ± 8.64b | 30.35 ± 1.01b | 0.93 ± 0.26c | 57.41 ± 16.13b | 109.27 ± 13.76b | 14.97 ± 5.52b | 329.63 ± 18.14b | 47.53 ± 3.98b | 9.48 ± 0.66b | 7.08 ± 0.84b | 36.32 ± 3.14c |
AM | 462.44 ± 101.61a | 39.45 ± 2.24a | 46.69 ± 13.51b | 119.22 ± 38.44a | 253.18 ± 54.89a | 26.26 ± 5.04a | 585.28 ± 113.65a | 44.56 ± 10.19b | 7.64 ± 1.14b | 7.05 ± 0.40b | 43.87 ± 4.60b |
D | |||||||||||
NM | 197.28 ± 11.94b | 28.67 ± 1.12c | 1.85 ± 0.75c | 65.86 ± 6.11b | 92.78 ± 9.81b | 23.22 ± 7.28ab | 344.99 ± 25.28b | 57.41 ± 5.22a | 11.04 ± 1.78a | 10.54 ± 2.01a | 49.55 ± 5.03b |
AM | 447.58 ± 69.30a | 37.26 ± 0.60a | 67.66 ± 6.23a | 124.36 ± 20.17a | 224.32 ± 56.72a | 20.63 ± 3.45ab | 563.12 ± 61.86a | 56.01 ± 5.39a | 11.87 ± 1.10a | 11.58 ± 0.85a | 58.38 ± 2.21a |
Two-way ANOVA | |||||||||||
D | ns | * | ns1 | ns | ns | ns | ns1 | ** | ** | ** | ** |
I | ** | ** | **1 | ** | ** | ns | **1 | ns | ns | ns | ** |
D × I | ns | ns | – | ns | ns | * | – | ns | ns | ns | ns |